Back
Results - Announcements
Lincoln Pharmaceuticals Ltd consolidated sales down 5.34% on year in Q2FY2026, net profit soared by 211.52%
13-Aug-2026, 01:21
Lincoln Pharmaceuticals Ltd share price slipped 1.06% to Rs 591.1 after the company's net profit saw a strong growth of 211.52% to Rs 36.23 crore, while revenue from operations eased by 5.34% to Rs 177.28 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 25.19 lakh crore, easing 4.25%. It has inched up 0.97% over last one week and heading higher by 11.17% in last one month while the market capitalization of Lincoln Pharmaceuticals Ltd has slipped by 3.02% and 8.36% in the same period respectively. Profit before tax (PBT) of Lincoln Pharmaceuticals Ltd stood at Rs 47.55 crore in Q2 FY26, expanding by 34.36% year-on-year, and surging by 184.73% quarter-on-quarter. EBITDA came in at Rs 3 crore, crashing by 62.88% YoY and nosediving by 89.09% sequentially. Total expenses slightly declined by 7.45% to Rs 153.73 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 58.58 crore, plunging by 20.55% YoY, while employee benefits expense was at Rs 33.31 crore, inching up 2.62% YoY. For the TTM ended FY26, revenue from operations inched higher 7.35% to Rs 623.23 crore, while net profit dropped 11.74% to Rs 82.35 crore, compared to previous TTM. EBITDA jumped by 6677% to Rs 79.01 crore, and PBT fell 10.68% to Rs 109.19 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 93.02 crore in FY26, as against Rs 63.22 crore in FY25. Lincoln Pharmaceuticals Ltd rallied 8.29% in last one year, significantly outperforming the benchmark BSE Sensex which has slipped by 2.83% during the same period.
Lincoln Pharmaceuticals Ltd share price slipped 1.06% to Rs 591.1 after the company's net profit saw a strong growth of 211.52% to Rs 36.23 crore, while revenue from operations eased by 5.34% to Rs 177.28 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 25.19 lakh crore, easing 4.25%. It has inched up 0.97% over last one week and heading higher by 11.17% in last one month while the market capitalization of Lincoln Pharmaceuticals Ltd has slipped by 3.02% and 8.36% in the same period respectively. Profit before tax (PBT) of Lincoln Pharmaceuticals Ltd stood at Rs 47.55 crore in Q2 FY26, expanding by 34.36% year-on-year, and surging by 184.73% quarter-on-quarter. EBITDA came in at Rs 3 crore, crashing by 62.88% YoY and nosediving by 89.09% sequentially. Total expenses slightly declined by 7.45% to Rs 153.73 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 58.58 crore, plunging by 20.55% YoY, while employee benefits expense was at Rs 33.31 crore, inching up 2.62% YoY. For the TTM ended FY26, revenue from operations inched higher 7.35% to Rs 623.23 crore, while net profit dropped 11.74% to Rs 82.35 crore, compared to previous TTM. EBITDA jumped by 6677% to Rs 79.01 crore, and PBT fell 10.68% to Rs 109.19 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 93.02 crore in FY26, as against Rs 63.22 crore in FY25. Lincoln Pharmaceuticals Ltd rallied 8.29% in last one year, significantly outperforming the benchmark BSE Sensex which has slipped by 2.83% during the same period.